Farnesol is the dephosphorylated form of farnesyl pyrophosphate, the last precursor common to all branches of the mevalonate pathway (1). The metabolic and biologic importance of farnesol has been recently demonstrated by several reports that identified the isoprenol as a natural nonsterol regulatory component of 3-hydroxy-3-methylglutaryl-CoA reductase activity (2-4) and an inhibitor of neoplastic cell growth (5, 6). Farnesol is catabolized into farnesal, farnesoic acid, and prenyl dicarboxylic acids (7, 8) . However, it can also be "re-phosphorylated" into farnesyl pyrophosphate and used for protein isoprenylation (9). The observation that shorter (C 10 , geraniol) and longer (C 20 , geranylgeraniol) isoprenols, which are metabolically and structurally related to farnesol, are devoid of biological activity (2, 3) suggest the existence of farnesol-specific cellular targets or binding sites. It has been proposed that farnesol inhibits the cytosol to membrane translocation of protein kinase C (PKC, 1 Ref. 10). An effect on PKC has also been observed with farnesylamine, a closely related structural analogue of farnesol (11). However, a direct effect on PKC is unlikely as farnesol does not affect PKC cellular localization in cell lines derived from normal tissue (12). Other studies have reported the existence of a farnesol-specific, orphan nuclear receptor in vertebrate cells, the farnesoid X-activated receptor, but the role of this receptor in cell signaling pathways still needs to be defined (13, 14) .
Farnesol is the dephosphorylated form of farnesyl pyrophosphate, the last precursor common to all branches of the mevalonate pathway (1) . The metabolic and biologic importance of farnesol has been recently demonstrated by several reports that identified the isoprenol as a natural nonsterol regulatory component of 3-hydroxy-3-methylglutaryl-CoA reductase activity (2) (3) (4) and an inhibitor of neoplastic cell growth (5, 6) . Farnesol is catabolized into farnesal, farnesoic acid, and prenyl dicarboxylic acids (7, 8) . However, it can also be "re-phosphorylated" into farnesyl pyrophosphate and used for protein isoprenylation (9) . The observation that shorter (C 10 , geraniol) and longer (C 20 , geranylgeraniol) isoprenols, which are metabolically and structurally related to farnesol, are devoid of biological activity (2, 3) suggest the existence of farnesol-specific cellular targets or binding sites. It has been proposed that farnesol inhibits the cytosol to membrane translocation of protein kinase C (PKC, 1 Ref. 10 ). An effect on PKC has also been observed with farnesylamine, a closely related structural analogue of farnesol (11) . However, a direct effect on PKC is unlikely as farnesol does not affect PKC cellular localization in cell lines derived from normal tissue (12) . Other studies have reported the existence of a farnesol-specific, orphan nuclear receptor in vertebrate cells, the farnesoid X-activated receptor, but the role of this receptor in cell signaling pathways still needs to be defined (13, 14) .
We have shown that mevalonate (MVA) availability is an important determinant of vascular tone in animal and human arteries (15, 16) . Decreased vascular MVA availability following treatment with lovastatin, a 3-hydroxy-3-methylglutarylCoA reductase inhibitor, was associated with an increase in the response to vasoconstrictors, whereas addition of MVA to the arteries inhibited vasoconstriction. These findings, together with the recently characterized metabolic importance of farnesol, led us to hypothesize that farnesol itself has vasoactive properties. In evaluating the functional properties of various farnesyl analogues in the vascular tissue (17), we indeed confirmed this hypothesis and observed that farnesol is a potent inhibitor of vasoconstriction which affects vascular tone in both animals and humans. The effect is rapid, dose-dependent, reversible, and specific of farnesol as geraniol and geranylgeraniol are inactive. The study further indicated that both GTPbinding protein-dependent contractions and those induced by KCl are inhibited by farnesol. We concluded that farnesol inhibits post-receptor and post-GTP-binding protein events and perhaps Ca 2ϩ channels. However, the precise mechanism of action of farnesol on modulating vasoconstriction remained elusive. In the present study, we have explored further the vasoactive properties of farnesol and document that farnesol 1) inhibits Ca 2ϩ signaling in arteries and vascular smooth muscle cells and 2) possesses Ca 2ϩ channel blocker properties.
EXPERIMENTAL PROCEDURES
Reagents-C 15 (farnesol), C 10 (geraniol), and C 20 (geranylgeraniol) isoprenols were purchased from Aldrich (trans-trans-farnesol, catalog number 27,754-1) and Sigma (trans-geraniol, product number G 5135, and all-trans-geranylgeraniol, product G 3278). Stock solutions of the isoprenols were prepared in ethanol. Fura-2/AM was purchased from * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Dept. 5 . After stretching for optimal tension recording and maximum stimulation ("wake-up" procedure consisting of three consecutive stimulations with a high (100 mM) potassium salt solution and 10 Ϫ6 M NE) (16 -18) , the arteries were incubated for 3 h at room temperature and for 1 h at 37°C in HBSS containing 50 M fura-2/AM (16) . Intravascular [Ca 2ϩ ] i was then determined using fluorescence ratios (340/380 nm excitation, 510 nm emission) as described previously (16, 19) . The experiments were conducted with a dual wavelength spectrofluorometer (Spex Industries, Inc., Edison, NJ), a Nikon microscope, and a 25 ϫ water-oil immersion Zeiss lens. Background fluorescence was determined before loading with fura-2 and subtracted from all fluorescence readings. Based upon our having shown previously that farnesol inhibits NE-and KCl-induced contraction (17) , determinations of [Ca 2ϩ ] i were conducted in basal conditions, and then after challenge with either a high K ϩ (100 mM KCl) depolarizing solution or NE. Active tension (mN/mm) was recorded simultaneously.
Cells-A10 and A7r5 cells were purchased from the American Type Culture Collection (Rockville, MD) and used between passages 7 and 25. A10 cells were cultured in RPMI medium 1640 with 10% fetal calf serum, streptomycin (30 g/ml), and penicillin (30 units/ml). A7r5 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and antibiotics. Both cell lines were cultured at 37°C under a 5% CO 2 atmosphere. All cell culture reagents were obtained from Life Technologies, Inc.
Determination of Intracellular Free [Ca 2ϩ ] i -A10 cells were grown to confluency on glass slides in 5% CO 2 -buffered RPMI medium 1640 containing 10% fetal calf serum and antibiotics. Intracellular [Ca 2ϩ ] i was determined in adherent cells, after a 30-min loading with 2 M fura-2/AM in HBSS as described previously (20) . Intracellular [Ca 2ϩ ] i was measured at base line first and then after the addition of either one of the following agonists: KCl, arginine-vasopressin (AVP), 12,13-phorbol myristate acetate (PMA), and thapsigargin.
Electrophysiology-Inward barium (I Ba ) currents were studied in single cells by the patch-clamp technique in the perforated-(nystatin) or cell-attached configuration (21) (22) (23) . In the perforated patch experiments, a List patch-clamp amplifier (model EPC 7) was used for current amplification and data acquisition; command potentials were controlled with commercial software programs using a CED1401 interface (Cambridge Electronic Design Ltd., Cambridge, UK). Currents were recorded from holding potential Ϫ80 mV during linear voltage ramps from Ϫ100 to ϩ100 mV at 0.67 V/s or 400 ms-step pulses to 0 mV (pulse frequency ϭ 0. . Nystatin (Biochrom KG, Berlin, Germany) was dissolved in Me 2 SO and diluted into the pipette solution to give a final concentration ranging from 50 to 100 g/ml. The resistance of the pipettes was 2 to 4 M⍀. Series resistance in perforated patch recordings was Ͻ20 M⍀.
In cell-attached patch experiments, the pipette solution contained (in mM) BaCl 2 110, Hepes 5, buffered to pH 7.4 with tetraethylammonium hydroxide. Patch pipettes were made of borosilicate glass and coated with wax to minimize capacitative transients and noise; pipette resistance was 7-10 M⍀. The recordings were made with a Biologic model RK 300 amplifier, filtered (Ϫ3 dB, 5-pole Tchebicheff filter) at 1 kHz and sampled at 5 kHz. Bath solution contained (in mM) potassium aspartate 140, MgCl 2 5, EGTA 5, Hepes 10, buffered to pH 7.4 with KOH.
The cells were continuously perfused during all recordings. Farnesol and other drugs were applied by changing the bath solution. Final concentrations of ethanol, the diluent, were 0.1% (v/v). Experiments were carried out at room temperature (20 -24°C) .
Vascular Reactivity Experiments with Permeabilized Arteries-Rat mesenteric arteries were mounted on an isometric myograph at room temperature, stretched for optimal tension recording, and challenged with KCl and NE for maximum stimulation. The arteries were then exposed for ϳ15 min to a Ca 2ϩ -free cytoplasmic salt solution (CSS, Refs.
25 and 26) containing 130 mM potassium propionate, 4 mM MgCl 2 , 4 mM Na 2 ATP, 2 mM Tris maleate, 10 mM creatine phosphate, 0.1 mg/ml creatine phosphokinase, and 4 mM EGTA (pH 6.8 at 22°C). The bath was emptied, and the arteries were covered with 10 l of CSS containing 2 mM EGTA and 1,000 units/ml Staphylococcus aureus ␣-toxin. After a 20-min incubation, the permeabilized arteries were washed 3 times with 4 mM EGTA-CSS, bathed in 2 mM EGTA-CSS, and exposed to cumulative addition of Ca 2ϩ using a concentrated (0.1 M) CaCl 2 solution. The bath was maintained at 20 -22°C during tension recording, and results were calculated as % of the maximum response obtained during wake up with KCl and NE. Free Ca 2ϩ concentrations were calculated as described previously (25) (26) (27) .
Statistical Analysis-Values are reported as mean Ϯ S.E. Differences were assessed using paired or unpaired Student's t tests as appropriate, and a p value Ͻ 0.05 was assumed to indicate a significant difference.
RESULTS

Effect of Farnesol on Ca
2ϩ Signaling in Isolated ArteriesAddition of KCl (100 mM) or NE (10 Ϫ5 M) to fura-2 loaded arteries induced a sharp [Ca 2ϩ ] i increase with slow (ϳ300 s) return to base line (not shown). Exposure of arteries to farnesol (30 M, 30-min incubation) reduced the peak [Ca 2ϩ ] i transients evoked by addition of NE to approximately 35% of control values (p Ͻ 0.0001, n ϭ 10, Fig. 1 ). As noted in our previous report (17) , NE-induced contractions were also reduced as follows: 2.40 Ϯ 0.18 mN/mm versus 3.84 Ϯ 0.24 mN/mm for farnesol and control, respectively (n ϭ 10, p Ͻ 0.001). Under similar conditions, geraniol and geranylgeraniol were inactive on both [ Fig. 2A ). The response to AVP was characterized by a large and rapid increase in [Ca 2ϩ ] i (AVP peak ϭ 293.6 Ϯ 17.1 nM, n ϭ 5) followed by a rapid decrease to a lower plateau (63.4 Ϯ 3.3 nM at 400 s). The rise in [Ca 2ϩ ] i is believed to result from both Ca 2ϩ influx and Ca 2ϩ release from intracellular stores, whereas the plateau corresponds to the opening of store-regulated and voltagesensitive plasma membrane Ca 2ϩ channels (28) . As shown in Fig. 2B , farnesol significantly reduced both phases of the response to AVP to 50.9 Ϯ 6.1 (peak) and 73.7 Ϯ 1.4% (plateau) of average control values (n ϭ 5, p Ͻ 0.01). ; n ϭ 5) to a maximum (TG peak ) followed by a sustained plateau phase at ϳ400 s after TG addition (TG 400 s ). This response is illustrated in Fig. 3A . In the absence of extracellular Ca 2ϩ , only the plateau phase was decreased (Fig. 3A) , and no modification of the onset and the rate of the [Ca 2ϩ ] i transient was observed. Farnesol decreased TG 400 s but did not affect TG peak (Fig. 3A) ; average TG 400 s values were 49.5 Ϯ 3.5 and 103 Ϯ 5.9 nM for farnesol and control, respectively (n ϭ 5, p Ͻ 0.006), whereas TG peak values were 83.7 Ϯ 5.1 and 114.0 Ϯ 5.6 nM (p ϭ not significant). Onset (8 Ϯ 1 s) and rate of the TG response (3 Ϯ 1 nmol ϫ liter Ϫ1 ϫ s Ϫ1 ) were not modified by farnesol (p ϭ not significant). In the absence of extracellular Ca 2ϩ , farnesol had no significant effect on either TG peak (92.2 Ϯ 4.4 versus 106.0 Ϯ 3.3 nM for farnesol and control, respectively; n ϭ 5, p ϭ not significant) or TG 400s (45.8 Ϯ 1.8 nM versus 55.8 Ϯ 1.9 nM, p ϭ not significant).
Effect of Farnesol on Thapsigargin-and PMA-dependent
As illustrated in Fig. 3B , addition of PMA to control cells induced a sharp rise of [Ca 2ϩ ] i to a maximum (PMA peak ϭ 80.0 Ϯ 5.7 nM from a base line of 30.6 Ϯ 3.1 nM, n ϭ 7) with a relatively long onset (35 Ϯ 7 s) as compared with TG transients. The peak response was followed by a slow decline in [Ca 2ϩ ] i . In the absence of extracellular Ca 2ϩ , no response to PMA was observed ( (Fig. 4, A and B (Fig. 4 , A-C) and was observed over the whole voltage range (Fig. 4, A and B) . Geraniol, applied to the bath solution at the same concentration (10 M, Fig. 4C ), did not modify Ca 2ϩ channel currents (peak current was reduced to 99 Ϯ 5% of the control values, n ϭ 5, p ϭ not significant). Geranylgeraniol (10 M, Fig. 4C ) had a modest but reversible effect (reduction to 89 Ϯ 3%, n ϭ 5, p Ͻ 0.02). No change in leak current was observed during application of the isoprenols suggesting that, at these concentrations, they had no "detergent-like" effect on cell plasma membrane. Half-maximal inhibition of the Ca 2ϩ channel current was observed at 2.2 mM farnesol (Fig. 4D) . The Hill coefficient was 0.82, indicating 1:1 binding of farnesol.
Effect of Farnesol on L-type Ca 2ϩ
Channel Activity: Cellattached Patch-In these experiments, the effect of farnesol on single L-type Ca 2ϩ channel within the patch was determined. I Ba were evoked every 10 s by either 400-ms pulses to Ϫ10 mV (from holding potential of Ϫ40 mV) or steady state recordings at Ϫ10 mV. Fig. 5  (middle) , the open probability was dramatically reduced in the presence of farnesol. Maximum, steady state inhibition was reached after approximately 3 min. No change in leak current was observed during farnesol application. The effect of farnesol was reversible as evidenced by recovery of unitary currents after wash out within 3-5 min (not shown) and full response to (Ϫ)-Bay K 8644 (Fig. 5, right) .
Effect of Farnesol on Ca 2ϩ
-dependent Contraction in ␣-Toxinpermeabilized Arteries-As shown in Fig. 6 ("basal" curves) , farnesol (30 M, 60-min incubation) did not inhibit significantly Ca 2ϩ -dependent contractions in permeabilized arteries. The Ca 2ϩ concentrations necessary to induce half-maximum contraction (pCa 50 ) were 732 Ϯ 102 and 724 Ϯ 78 nM for control and farnesol-treated vessels, respectively (p ϭ not significant, n ϭ 4). The response to Ca 2ϩ was also determined in the presence of GTP␥S, a non-hydrolyzable form of GTP, and in the presence of PMA, a PKC activator (30) . As previously reported (31, 32), both compounds shifted the Ca 2ϩ dose-response curve to the left, indicating an increased sensitivity of the artery to Ca 2ϩ (Fig. 6 , GTP␥S and PMA curves). However, the sensitizing effect of GTP␥S and PMA was not modified by farnesol (same figure).
DISCUSSION
This study was conducted to elucidate the molecular mechanisms by which farnesol, a natural endogenous intermediate of the mevalonate pathway, inhibits vasoconstriction. Because elevation of intracellular Ca 2ϩ concentration in response to either membrane depolarization or vasoconstrictors is the main trigger for vascular smooth muscle contraction (33), we first characterized the effect of farnesol on Ca 2ϩ signaling. Experiments were conducted in both intact arteries and isolated vascular smooth muscle cells loaded with fura-2, a fluorescent cytosolic Ca 2ϩ indicator (34) . For the experiments with vascular smooth muscle cells, the clonal A10 cell line was used (35) . These cells do not contract and do not respond to NE. However, they do respond to KCl and to arginine-vasopressin by elevating [Ca 2ϩ ] i and were therefore chosen to examine the impact of farnesol on Ca 2ϩ signaling at the cellular level. It must be mentioned that farnesol inhibits contractions induced by AVP in intact arteries (36) , thus further justifying the use of the cell line in elucidating the mechanism of action of farnesol.
The results of these experiments indicate that farnesol decreases agonist and depolarization-dependent [Ca 2ϩ ] i transients in arteries and vascular smooth muscle cells. These findings suggest that inhibition of contraction is the consequence of reduced Ca 2ϩ signaling in the presence of farnesol. Interestingly, farnesol also decreases basal arterial [Ca 2ϩ ] i ; this may explain our previous observation of a vasodilatory action of farnesol on resting human arteries, i.e. in the absence of agonist (17) . The greater impact of farnesol on the KCl response compared with the AVP response observed in our cell experiments suggests that the primary action of farnesol is on plasma membrane-dependent Ca 2ϩ influx, i.e. voltage-depend-
FIG. 4. Effect of farnesol on L-type Ca 2؉ channel currents in vascular smooth muscle cells (perforated patch-clamp experiments).
Currents were recorded from holding potentials of Ϫ80 mV during linear voltage ramps at 0.67 V/s from Ϫ100 to ϩ100 mV (A and B) or 400-ms step pulses to 0 mV (C). I Ba indicates total inward Ba 2ϩ current. Currents were recorded before (Con.), after (1 min) application of farnesol, and after removal of the farnesol from the bath (w.o.). Geraniol and geranylgeraniol were applied at a concentration of 10 M (C). A-C, representative traces; D, mean dose-response curve of farnesol-induced inhibition of Ba 2ϩ -channel currents in A7r5 cells (n ϭ 5). Data points were fitted to the logistic function: % of I max ϭ 100/(1 ϩ (X/IC 50 ) n ); I max is the maximal I Ba after farnesol inhibition, X is the farnesol concentration applied to the cell, IC 50 is the concentration of half-maximal inhibition, and n is the Hill coefficient.
Farnesol and Smooth Muscle Ca 2ϩ Signaling
ent Ca 2ϩ channels, and not on Ca 2ϩ release from intracellular stores. However, the reduction by farnesol of the peak response to AVP indicates a possible effect of farnesol on intracellular stores as both release from the stores and Ca 2ϩ influx overlap during this phase of the response.
The issue of the origin of the reduction in Ca 2ϩ signaling was further explored in another series of experiments in which TG, a specific inhibitor of endoplasmic reticulum Ca 2ϩ -ATPase (37), and PMA, a PKC activator, were used. The data show that farnesol mimics the effect of extracellular Ca 2ϩ removal on both TG-and PMA-induced Ca 2ϩ ] i transients. As to the TG response, farnesol decreases TG 400 s without affecting TG peak . Studies by others have suggested that the peak response to TG reflects the Ca 2ϩ leak from endoplasmic reticulum, inositol 1,4,5-trisphosphate-sensitive stores, and the plateau reflects activation of Ca 2ϩ influx across plasma membrane (38) . Indeed, in the absence of extracellular Ca 2ϩ , only the plateau phase was decreased (Fig. 3A) . Although these results do not exclude the possibility that other cellular Ca 2ϩ stores implicated in Ca 2ϩ signaling such as the caffeine-sensitive, thapsigargininsensitive Ca 2ϩ stores (39) could be affected by farnesol, they strongly suggest that farnesol inhibits Ca 2ϩ entry from extracellular space and does not impact on the endoplasmic reticulum Ca 2ϩ stores. An inhibitory effect of farnesol on Ca 2ϩ entry was further supported by the observation that farnesol abolishes the [Ca 2ϩ ] i response to PMA. In our experimental conditions, this response is the sole consequence of an activation of plasma membrane Ca 2ϩ influx since it is totally inhibited by extracellular Ca 2ϩ removal (Fig. 3B) . It is actually possible that in A10 cells, the phorbol ester action on [Ca 2ϩ ] i is mediated by an activation of L-type Ca 2ϩ channels as observed in A7r5 cells, another rat aortic smooth muscle cell line (40) . This possibility, together with our observation that KCl-dependent contraction and KCl-dependent Ca 2ϩ signaling are strongly inhibited by farnesol, led us to postulate that the primary targets of farnesol were plasma membrane, voltage-dependent Ca 2ϩ channels present in vascular smooth muscle cells. Histogram analysis shows no significant Ca 2ϩ channel activity. Right, consecutive currents after wash out of farnesol (no carrier protein was included during wash out) and application of 1 M (Ϫ)-Bay K 8644. Histogram analysis shows peaks corresponding to 1 and 2 simultaneous openings at Ϫ1.6 and Ϫ3.2 pA, respectively. The enhanced activity compared with control sweeps is due to the higher concentration of (Ϫ)-Bay K 8644 (1 M versus 50 nM in control conditions). This concentration of (Ϫ)-Bay K 8644 was chosen to show recovery of full functionality of the channels after block by farnesol. Inhibition of unitary barium currents by farnesol was observed in n ϭ 5 independent experiments.
Therefore, direct measurement of the activity of voltage-dependent Ca 2ϩ channels was performed, using the patch-clamp techniques. The data, established in two different cell lines (A10 and A7r5) indicate that farnesol blocks vascular smooth muscle L-type Ca 2ϩ channels (IC 50 ϳ 2 M, Fig. 4 ). This effect is reversible and specific of the C 15 structure since geraniol, C 10 , is inactive, and geranylgeraniol, C 20 , has only a limited inhibitory action on channel activity (10% inhibition of peak Ca 2ϩ currents for a concentration of 10 M as compared with 70% with equimolar concentration of farnesol).
The specificity of farnesol over geranylgeraniol may be only apparent and due to differences in solubility. Indeed, partition coefficients (logP) are 4.62 and 6.59 for farnesol and geranylgeraniol, respectively, indicating a 100-fold difference between the two isoprenols (by comparison, logP for geraniol ϭ 2.65). However, biological activity does not necessarily correlate with biophysical constants (41) . Considering that hydrophobicity favors both membrane incorporation and membrane permeability (42) , and assuming a membrane site of action for the isoprenols, one could expect a greater effect of geranylgeraniol over farnesol. Elucidation of the exact cellular site of action of farnesol together with precise determination of actual membrane concentration using radiolabeled compounds and purified membrane preparations will help clarify this issue in the future.
Whether Ca 2ϩ channel inhibition occurs within a "physiological" range of farnesol concentrations can only be speculated at this point. To our knowledge, there is no report documenting extracellular or plasma farnesol concentrations, and there is only one report (43) that gives a range of farnesol tissue concentration (approximately 50 -200 ng/g wet weight of rat liver). Assuming a tissue water content of 70% and a homogeneous distribution, the calculated concentration of farnesol in hepatic tissue would be 0.1 to 1.2 M. This is similar to the low range of farnesol concentrations active on Ca 2ϩ channels and suggests that, providing similar concentrations are also present in the vascular tissue, our findings are physiologically meaningful.
Our study has not specifically examined the mechanism of action of farnesol on Ca 2ϩ channels. However, we believe that our experiments already exclude a number of possible mechanisms whereby farnesol might inhibit Ca 2ϩ channels, in particular those that involve messenger molecules such as PKC, cyclic nucleotides, and GTP-binding (G) proteins.
As discussed below, our ␣-toxin experiments (Fig. 6 ) indicate that farnesol does not affect PKC activity. Moreover, our experiments with intact vessels show that farnesol inhibits KClinduced contraction, a response that is not attenuated by downregulation of the enzyme (44) . Thus, primary inhibition of PKC by farnesol with secondary inhibition of voltage-gated channels is unlikely. The participation of cyclic nucleotides, cAMP and cGMP, to the inhibitory effect of farnesol was not explored directly in our study but is also unlikely as both nucleotides have been shown to decrease the sensitivity (shift to the right) of the smooth muscle to Ca 2ϩ when tested in ␣-toxin-permeabilized (rat mesenteric) arteries (45) . As shown in Fig. 6 , in no instance (basal, PMA, or GTP-␥S curves) do we see a significant shift of the Ca 2ϩ dose-response curve to the right. Alternatively, farnesol may inhibit one of the G proteins known to stimulate L-type Ca 2ϩ channels. A direct regulation of L-type Ca 2ϩ channels by G s has been demonstrated in cardiac cells (46) . This pathway may also be functional in A7r5 cells (47) . Similarly, G i has been implicated in the adrenergic activation of dihydropyridine-sensitive Ca 2ϩ currents in rat portal vein myocytes (48) . However, G s inhibition (with GDP␤S) does not reduce significantly basal Ca 2ϩ channel activity (46, 49, 50) , and G i inhibition with specific antibodies reduces Ca 2ϩ currents only after receptor activation (48) . As shown in Figs. 4 and 5, farnesol inhibits A10 and A7r5 L-type currents in the absence of any specific activation of the G protein pathway. Finally, a G q /G 11 -mediated regulation of the dihydropyridine-sensitive Ca 2ϩ channels was described recently by Mironneau and Macrez-Lepretre (51) in rat portal vein myocytes. However, the study suggests that the G q /G 11 effect on the channels is secondary to Ca 2ϩ release from intracellular stores; as shown in Fig. 3A (thapsigargin response) , farnesol does not significantly affect this response. Thus, our results do not support the hypothesis of a G protein-mediated effect of farnesol on vascular smooth muscle L-type Ca 2ϩ channels.
Altogether, and by exclusion, we believe that farnesol may act directly on the channels. The presence of farnesol inside cells and tissues actually raises the question of its site of action. The results of our perforated patch experiments, in which farnesol is added to the bath and the activity of Ca 2ϩ channels located outside of the patch pipette is measured, point to an extracellular action of farnesol on the channels. It is possible although that after addition to the bath and because of its hydrophobicity farnesol crosses the plasma membrane and blocks Ca 2ϩ channels from the intracellular side. Cell-attached experiments were conducted to provide further insight on this issue. Their results indicate that farnesol inhibits the Ca 2ϩ channels present within the patch, in tight seal configuration. One of the most likely explanations for the effect of farnesol in these conditions is that farnesol first diffuses intracellularly through the plasma membrane and then reaches its site of action within the patch from the cytosolic side of the membrane. Such a mechanism has been proposed for methoxyverapamil, a Ca 2ϩ channel blocker of the phenylalkylamine class (52) Alternatively, a lateral diffusion of farnesol in the lipids of the plasma membrane followed by binding to an intra-membrane site of the channel could be postulated, as proposed for dihydropyridine-like Ca 2ϩ channel blockers (53) . Although the issue of the exact site of action of farnesol cannot be fully resolved with the present data, our results strongly suggest that intracellularly produced farnesol is capable of interacting with plasma membrane L-type Ca 2ϩ channels and thus support the concept of farnesol being a natural, endogenous Ca 2ϩ channel blocker. Contraction also depends on the functional integrity of vascular smooth muscle Ca 2ϩ -sensitive pathways, which include enzymes directly activated by Ca 2ϩ as well as systems controlling the sensitivity of the smooth muscle to Ca 2ϩ (26, 54) . The possibility that farnesol might inhibit these pathways was then examined in a last series of experiments conducted in ␣-toxinpermeabilized arteries. In these preparations, Ca 2ϩ -sensitive pathways can be studied directly since intravascular [Ca 2ϩ ] i is controlled using EGTA-containing buffer solutions, and the regulation of [Ca 2ϩ ] i by Ca 2ϩ channels and intracellular stores is bypassed. The data indicate that farnesol has no direct effect on the Ca 2ϩ -responsive elements implicated in arterial contraction, including those activated by GTP and PKC. The absence of effect of farnesol in ␣-toxin-permeabilized arteries is not due to its inability to penetrate the tissue, because farnesol is a small molecular weight (M r ϭ 222.4) molecule and is likely to diffuse freely inside the arterial smooth muscle cells through the pores created by the toxin (54, 55) . Therefore, our findings suggest that the vascular action of the isoprenol is solely the consequence of its inhibition of Ca 2ϩ signaling. In conclusion, we have shown that farnesol reduces Ca 
in smooth muscle contraction beyond Ca 2ϩ signaling and point to the plasma membrane as a primary site of cellular action. These properties of farnesol are not shared by other metabolically related isoprenols and likely account for its inhibitory effect on vasoconstriction. Blocking Ca 2ϩ signaling with specific compounds has been the focus of intensive pharmacological research and the goal of several therapeutic strategies including those applied to the treatment of hypertension and atherosclerosis. Since farnesol is an intermediate of the mevalonate pathway, our findings are consistent with farnesol acting as a natural, endogenous Ca 2ϩ blocker and suggest that controlling intracellular levels of farnesol or farnesol analogues might be useful in the regulation of vascular tone in vivo.
